Chromatin immunoprecipitation-on-chip reveals stress-dependent p53 occupancy in primary normal cells but not in established cell lines

Cancer Research

Volumn 68, Issue 23, 2008, Pages 9671-9677

  Shaked, Helena ^a   Shiff, Idit ^a   Kott Gutkowski, Miriam ^b   Siegfried, Zahava ^a   Haupt, Ygal ^a   Simon, Itamar ^a,c  

^a HEBREW UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL FATE; CELL TYPE; CELLULAR STRESS RESPONSE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA BINDING; GENE EXPRESSION; GENOTOXICITY; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TRANSCRIPTION INITIATION;

CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; DNA DAMAGE; DNA, NEOPLASM; DOXORUBICIN; FIBROBLASTS; GENES, P53; HCT116 CELLS; HUMANS; MICROCHIP ANALYTICAL PROCEDURES; PROMOTER REGIONS, GENETIC; TELOMERASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 57149118022     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0865     Document Type: Article

References (35)

1. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007;8:275-83.
2. Haupt S, Haupt Y. Manipulation of the tumor suppressor p53 for potentiating cancer therapy. Semin Cancer Biol 2004;14:244-52.
3. Haupt S, Haupt Y. Importance of p53 for cancer onset and therapy. Anticancer Drugs 2006;17:725-32.
4. Meek DW. Mechanisms of switching on p53: a role for covalent modification? Oncogene 1999;18:7666-75.
5. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003;10:431-42.
6. Vousden KH. Outcomes of p53 activation-spoilt for choice. J Cell Sci 2006;119:5015-20.
7. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001;8:781-94.
8. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002;416:560-4.
9. Oda K, Arakawa H, Tanaka T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000;102:849-62.
10. Knights CD, Catania J, Di Giovanni S, et al. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol 2006;173:533-44.
11. Sykes SM, Mellert HS, Holbert MA, et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 2006;24:841-51.
12. Tang Y, Luo J, Zhang W, Gu W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 2006;24:827-39.
13. Le Cam L, Linares LK, Paul C, et al. E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell 2006;127:775-88.
14. Huang J, Perez-Burgos L, Placek BJ, et al. Repression of p53 activity by Smyd2-mediated methylation. Nature 2006;444:629-32.
15. Ceribelli M, Alcalay M, Vigano MA, Mantovani R. Repression of new p53 targets revealed by ChIP on chip experiments. Cell Cycle 2006;5:1102-10.
16. Espinosa JM, Verdun RE, Emerson BM. p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol Cell 2003;12:1015-27.
17. 2/M promoters. Mol Cell Biol 2005;25:3737-51.
18. Kaeser MD, Iggo RD. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci U S A 2002;99:95-100.
19. Wei CL, Wu Q, Vega VB, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006;124:207-19.
20. Lee TI, Johnstone SE, Young RA. Chromatin immunoprecipitation and microarray-based analysis of protein location. Nat Protocol 2006;1:729-48.
21. Beckstette M, Homann R, Giegerich R, Kurtz S. Fast index based algorithms and software for matching position specific scoring matrices. BMC Bioinformatics 2006;7:389.
22. Horn HF, Vousden KH. Coping with stress: multiple ways to activate p53. Oncogene 2007;26:1306-16.
23. Brummelkamp TR, Fabius AW, Mullenders J, et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2006;2:202-6.
24. Sedelnikova OA, Horikawa I, Zimonjic DB, Popescu NC, Bonner WM, Barrett JC. Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat Cell Biol 2004;6:168-70.
25. Mendrysa SM, Perry ME. The p53 tumor suppressor protein does not regulate expression of its own inhibitor, MDM2, except under conditions of stress. Mol Cell Biol 2000;20:2023-30.
26. Noble JR, Zhong ZH, Neumann AA, Melki JR, Clark SJ, Reddel RR. Alterations in the p16(INK4a) and p53 tumor suppressor genes of hTERT-immortalized human fibroblasts. Oncogene 2004;23:3116-21.
27. Espinosa JM, Emerson BM. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell 2001;8:57-69.
28. Barlev NA, Liu L, Chehab NH, et al. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 2001;8:1243-54.
29. Luo J, Li M, Tang Y, Laszkowska M, Roeder RG, Gu W. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci U S A 2004;101:2259-64.
30. White DE, Talbott KE, Arva NC, Bargonetti J. Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription. Cancer Res 2006;66:3463-70.
31. Das S, Raj L, Zhao B, et al. Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation. Cell 2007;130:624-37.
32. Budhram-Mahadeo VS, Bowen S, Lee S, et al. Brn-3b enhances the pro-apoptotic effects of p53 but not its induction of cell cycle arrest by cooperating in transactivation of bax expression. Nucleic Acids Res 2006;34:6640-52.
33. Homer C, Knight DA, Hananeia L, et al. Y-box factor YB1 controls p53 apoptotic function. Oncogene 2005;24:8314-25.
34. Schumm K, Rocha S, Caamano J, Perkins ND. Regulation of p53 tumour suppressor target gene expression by the p52 NF-κB subunit. EMBO J 2006;25:4820-32.
35. Wei G, Li AG, Liu X. Insights into selective activation of p53 DNA binding by c-Abl. J Biol Chem 2005;280:12271-8.